Becton Dickinson & Co. Price Target Increased to $112.00 by Analysts at Barclays (BDX)
Barclays boosted their price objective on shares of Becton Dickinson & Co. (NYSE:BDX) from $106.00 to $112.00 in a research note issued on Thursday, American Banking and Market News reports. The firm currently has an “underweight” rating on the stock. Barclays’ price objective points to a potential downside of 0.13% from the stock’s previous close.
Shares of Becton Dickinson & Co. (NYSE:BDX) traded up 0.96% during mid-day trading on Thursday, hitting $112.15. 650,074 shares of the company’s stock traded hands. Becton Dickinson & Co. has a 1-year low of $81.08 and a 1-year high of $111.47. The stock’s 50-day moving average is $108.5 and its 200-day moving average is $103.. The company has a market cap of $21.768 billion and a price-to-earnings ratio of 17.10.
Becton Dickinson & Co. (NYSE:BDX) last posted its quarterly earnings results on Tuesday, November 5th. The company reported $1.52 EPS for the quarter, beating the Thomson Reuters consensus estimate of $1.46 by $0.06. The company had revenue of $2.10 billion for the quarter, compared to the consensus estimate of $2.05 billion. During the same quarter last year, the company posted $1.42 earnings per share. Becton Dickinson & Co.’s revenue was up 6.8% compared to the same quarter last year. Analysts expect that Becton Dickinson & Co. will post $6.21 EPS for the current fiscal year.
A number of other firms have also recently commented on BDX. Analysts at Merrill Lynch upgraded shares of Becton Dickinson & Co. to a “neutral” rating in a research note to investors on Tuesday. Separately, analysts at Bank of America Corp. upgraded shares of Becton Dickinson & Co. from an “underperform” rating to a “neutral” rating in a research note to investors on Tuesday. They now have a $95.00 price target on the stock, down previously from $117.00. Finally, analysts at Jefferies Group reiterated a “buy” rating on shares of Becton Dickinson & Co. in a research note to investors on Sunday, November 17th. They now have a $120.00 price target on the stock. One analyst has rated the stock with a sell rating, seven have given a hold rating and eight have issued a buy rating to the stock. Becton Dickinson & Co. has a consensus rating of “Hold” and an average target price of $110.46.
Becton, Dickinson and Company (NYSE:BDX) is a global medical technology company engaged in the development, manufacture and sale of medical devices, instrument systems and reagents used by healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.